Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A big steamy dog pile here. 50 cents then split..
Beat this dog down like the dog it is...poc..
A bio company to stupid to communicate. Morons..
Idera Pharmaceutical (IDRA)
1.03 ? 0.01 (0.98%)
Volume: 225,158 @09/22/21 7:05:55 PM EDT
Bid Ask Day's Range
1.03 1.05 1.01 - 1.0501
IDRA Detailed Quote
Hey corporate...get ready for a kick in the pants. Your silence is going to cost you now. Morons..
Corporate.....
Because your so inept in communicating, theirs aggressive institutional or market maker shorts on your tail... You f n morons..
Not so fast.. A lot of tape painting here.
Idera Pharmaceutical (IDRA)
1.06 ? -0.04 (-3.64%)
Volume: 514,435 @09/03/21 4:28:31 PM EDT
Bid Ask Day's Range
1.05 1.06 1.06 - 1.115
IDRA Detailed Quote
Could Could have a strong close today. Chart is long over duefor a retrace. Been firming up nicely. Lots of insider buys and streamlined biz. Waiting on pipeline disclosure or suitor here.
Pre market activity is interesting today. Long weekend to wrap up mergers??
Corporate communication sucks. EOM..
Idera Pharmaceutical (IDRA)
1.07 ? -0.02 (-1.83%)
Volume: 300,405 @09/01/21 5:21:43 PM EDT
Bid Ask Day's Range
1.07 1.1 1.07 - 1.11
IDRA Detailed Quote
Corporate should communicate their prospective pipeline stated in their eearnings. The mouth that doesn't open doesn't get fed..
Insider buys and inductive grants are bullish, as well as reduced and streamlined work force. Just waiting for the suitor announcement..
Idera Pharmaceutical (IDRA)
1.09 ? 0.0 (0.00%)
Volume: 152,531 @09/01/21 12:23:45 PM EDT
Bid Ask Day's Range
1.09 1.1 1.07 - 1.11
IDRA Detailed Quote
Hello Corporate?? How about a bone??
Corporate silence seeing is beyond the pale imo. They suggested pipeline add on's and zip since earnings. The mouths that open get fed?!
It it breaks a dollar. look out below.
Idera Pharmaceutical (IDRA)
1.08 ? -0.02 (-1.82%)
Volume: 435,729 @08/13/21 7:58:11 PM EDT
Bid Ask Day's Range
1.08 1.11 1.08 - 1.12
IDRA Detailed Quote
Wish I knew how to value book value of a startup biotech.
Anything down here is cheap. Below book value...insiders been buying knowing that as well..
Nice timing on that buy.
Yep. Added on this recent dip. I can wait for a better return here than most fluff and dump plays.
Their IP portfolio would be very important to an acquirer.
Scant volume mopping up the fringe holders. Plenty of inside skin in purchases and wouldn't surprise me to see additional buys at these levels. Ridiculously below book value here.
I don't know but from everything I've gathered and assessed here, imo this is an acquisition play. From the reduction of employees to insider purchase levels, share structure, potential pipeline, book value, nols, etc..
Have they recruited a new Medical Officer yet?
Insider buys are about as clearan indicator you can get. 50 million outstanding which is relatively small for the bio plays. Add a 50% reduction to the work force and it adds up to a buyout. See you in the big monies.
A lot of insider buys here. No brainer. I'll be adding tomorrow.
Idera Pharmaceutical (IDRA)
1.13 ? 0.02 (1.80%)
Volume: 801,864 @07/09/21 7:53:41 PM EDT
Bid Ask Day's Range
1.12 2.07 1.09 - 1.15
IDRA Detailed Quote
Expecting a massive run up as this has retraced and consolidated at text book steps. Insider purchases and corporate restructurings ear mark indications of buy out and or milestone accomplishments pending. Look for early week shake and launch.
yes Idera Pharmaceutical (IDRA)
1.34 ? -0.24 (-15.19%)
Volume: 23,269,791 @06/23/21 7:59:59 PM EDT
Bid Ask Day's Range
1.34 1.35 1.31 - 1.71
IDRA Detailed Quote
IDRA may be starting to build a base here.
Just getting started. The beginning of the beginnings.
i like da volume - IDRA
Bid: 1.40 Ask: 1.41 Last: 1.40 Chg ($): 0.285 Vol:
i am not surprised @ market action today Idera Pharmaceutical (IDRA)
1.4382 ? 0.3182 (28.41%)
Volume: 19,986,739 @06/22/21 12:08:04 PM EDT
Bid Ask Day's Range
1.43 1.44 1.21 - 1.45
IDRA Detailed Quote
a.h. pps 'Idera Pharmaceuticals, Inc. (IDRA)' mmm boy's looking fer shares
strong a.h. trading pps upticks
Shares Price Time Price Shares
Asks 10 1.44 18:41:06 1.28 487
2,000 1.41 18:41:06 1.28 100
12,650 1.40 18:41:06 1.28 100
250 1.39 18:41:06 1.28 100
1,000 1.31 18:37:54 1.28 100
Bids 3 1.12 18:18:45 1.28 100
2,500 1.10 18:11:47 1.28 100
425 1.08 17:59:46 1.30 8
2,300 1.05 17:59:42 1.30 100
100 1.01 17:59:26 1.28 100
Last updated
$IDRA FIVE YR.
[-chart]www.stockscores.com/chart.asp?TickerSymbol=idra&TimeRange=1825&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
$IDRA FIVE YR.
$IDRA Explanation of Responses: FORM-4
Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SOLAND DANIEL B
C/O IDERA PHARMACEUTICALS, INC.
505 EAGLEVIEW BOULEVARD, SUITE 212
EXTON, PA 19341
CHIEF OPERATING OFFICER
June 21 2021 - 04:11PM
Edgar (US Regulatory)
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response
Signatures
/s/ Daniel B. Soland 6/21/2021
**Signature of Reporting Person Date
https://ih.advfn.com/stock-market/NASDAQ/idera-pharmaceuticals-IDRA/stock-news/85409065/statement-of-changes-in-beneficial-ownership-4
i updated ibox 06-21-2021 'Idera Pharmaceuticals, Inc. (IDRA)' $IDRA looks to be buyout company
No warrants on the markets. Not sure on their insider or financial. None stand out per my last review of financials or 10q. Weekend homework?
does $IDRA have wts
Bargain bin buys here. Major upside gap fill is going to happen. Corporate clean up for take out imo. Options are dirt cheap.
Followers
|
122
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3443
|
Created
|
04/10/08
|
Type
|
Free
|
Moderators |
IDRA [NASD] https://www.otcmarkets.com/stock/IDRA/overview |
Idera Pharmaceuticals, Inc. |
We’re devoted to redefining the treatment of cancer and rare diseases where serious unmet needs exist.
https://www.iderapharma.com/our-company/
https://www.iderapharma.com/who-we-help/
https://www.iderapharma.com/our-approach/toll-like-receptor-immune-modulation/
Toll-like receptors (TLRs) are a class of proteins that are an important part of the innate immune system.
They alert the body to potential danger by recognizing pieces of bacteria, viruses, or damaged cells.
They essentially act like a smoke alarm, warning the body when trouble is detected.
Our lead investigational agent, tilsotolimod, activates TLR9. In cancer patients with solid tumors,
tilsotolimod is injected directly into a tumor to trigger TLR9 into action and prime a local immune response to help attack the tumor.
This has been demonstrated in pre-clinical models, and our translational studies during early clinical trials have shown rapid immune
activation in the injected tumor along with systemic increases in T cells.
Idera is investigating the combination of tilsotolimod with checkpoint inhibitors and other immune activators with the aim of providing improved outcomes for patients in need.
https://www.iderapharma.com/our-approach/key-publications/
https://www.iderapharma.com/areas-of-focus/oncology/immuno-oncology/
https://www.iderapharma.com/pipeline-programs/
TUMOR TYPE |
| |||||||
---|---|---|---|---|---|---|---|---|
Anti-PD-1 Refractory Advanced Melanoma |
| |||||||
Microsatellite-Stable Colorectal Cancer |
| |||||||
Resistant Solid Tumors |
| |||||||
Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
|
1 Tilsotolimod is an investigational agent which has not been approved by any regulatory authority
IDRA [NASD] |
Idera Pharmaceuticals, Inc. |
Healthcare | Biotechnology | USA |
Shs Outstand | 41.19M |
Shs Float | 38.72M ,
|
52W Range | 0.97 - 6.14 |
52W High | -81.76% |
Insider Own | 1.30% |
Inst Own | 19.70% |
Book/sh | 1.03 |
Cash/sh | 0.84 |
Employees | 32 |
Debt/Eq | 0.00 no short term either |
The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9,
such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400.
The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis.
It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication.
IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company
or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial.
The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.
In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens.
It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs,
are nucleic acid-based and represent a novel approach to selectively, silence gene expression.
It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents.
In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer,
it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies,
and TLR3 agonists for use as vaccine adjuvants.
IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection.
The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection,
one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin,
an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection.
In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers.
Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies.
In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.
The Company competes with Dynavax Technologies Corporation,
GlaxoSmithKline plc.,
Pfizer, Inc.,
VentiRx Pharmaceuticals.,
Novartis,
Dynavax Technologies Corporation,
VaxInnate, Inc.,
Intercell AG,
Cytos Biotechnology AG and
Celldex Therapeutics, Inc.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |